Two NEJM randomized trials in four months — SWiFT and TOWAR — both failed to show prehospital whole blood is superior to component therapy. Here's what the numbers actually say, what they don't, and what your program should do this week.

The largest randomized trial ever run on prehospital whole blood, SWiFT, found it no better than component therapy. Here is what the trial actually says, what it doesn't, and what it means for your cooler, your protocol, and your budget.